NCT02378662终止2 期
Safety & Efficacy of Prolonged Physiologic Erythropoietin (EPO) Level Treatment of Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)Using MDGN201 TARGTEPO
Aevi Genomic Medicine, LLC, a Cerecor company2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2015年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum Erythropoietin (EPO) Levels Above Baseline
研究概览
简要总结
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
详细描述
This is a Phase II, open-label study. Each patient will receive targeted dose of Erythropoietin (EPO) delivered via TARGTEPO.
The targeted doses will be determined according to 2 cohorts as follows: Group A (18-25 IU/Kg/day), Group B (35-45 IU/Kg/day). The objective is to evaluate safety and biologic activity of TARGTEPO treatment when maintaining Hb levels within the target range of 9-12 g/dl. Biological activity assessments will include duration of TARGTEPO secretion as measured by serum EPO levels above baseline.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject diagnosed with Anemia due to Chronic Renal Failure CKD stage 5 on peritoneal dialysis treatment for at least 6 months. Average Hb during last month between 9 to 12g/dL.
- •Serum albumin >3.2
- •Subjects with adequate iron stores (transferrin saturation > 20.0% and/or ferritin >100 ng/ml).
排除标准
- •Uncontrolled hypertension (defined as diastolic blood pressure > 110 mmHg or systolic blood pressure > 180 mmHg during screening).
- •Subjects who receive oral anti-coagulation treatment (e.g. warfarin)
- •Subjects who receive Acetyl Salicylic Acid (ASA) above 325 mg/day or patients who receive ASA treatment between 100mg/d and 325 mg/d who cannot discontinue it for 1 week prior to each Harvest or Implantation procedure
- •Congestive heart failure (New York Heart Association functional class III or IV).
- •Grand mal seizures within 2 years of the screening visit.
- •Clinical evidence of severe hyperparathyroidism as defined by PTH levels of > 10 times the upper normal limits.
- •Major surgery within 12 weeks of the screening visit.
- •Systemic hematologic diseases (e.g., sickle cell anemia, thalassemia (excluding Thalassemia minor), myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia).
- •Current systemic infection, active inflammatory disease, or malignancy under active treatment.
- •Subjects known to have tested positive at any time in the past for antibodies to erythropoietic proteins.
- •Subject has history of malignancy within the past 2 years prior to the screening visit, with the exception of basal cell carcinoma.
- •Subjects with other concurrent severe and/or uncontrolled medical condition which could compromise participation in the study (i.e. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive heart failure, unstable angina, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within six months, uncompensated cirrhosis, active upper GI tract ulceration).
- •Subject is currently enrolled in, or has not yet completed a period of at least 30 days or five half-lives of the investigational drug whichever is longer, since ending other investigational device or drug trial(s) prior to Screening phase.
- •Psychiatric, addictive, or any other disorder that compromises ability to provide informed consent for participation in this study.
- •Female subjects of child-bearing potential and males that do not agree to use acceptable methods of contraception during the study.
- •Pregnant and lactating female subjects.
- •Chronic alcoholic or drug abuse subjects.
- •Steroid or other immunosuppressive treatment (other than topical or inhaled steroids).
- •Subjects unwilling or unable to comply with the study procedures.
- •EPO Naïve subjects.
- •Known sensitivity to Gentamycin and Amphotericin
- •History of chronic or active Hepatitis B and/or C infection or positive serology at screening and known positive HIV or positive serology at screening.
- •Subject had blood transfusion within 84 days prior to Screening visit.
- •Subject has a date for renal transplantation.
- •Refer to the USPI - Depo-Medrol - Methylprednisolone Acetate - Injectable (Appendix A) for any concomitant drug taken by the patient which its interaction with Depo-Medrol will warrant exclusion from this protocol.
研究组 & 干预措施
Group B
Experimental
MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
干预措施: MDGN201 TARGTEPO (Biological)
Group A
Experimental
MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
干预措施: MDGN201 TARGTEPO (Biological)
结局指标
主要结局
Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum Erythropoietin (EPO) Levels Above Baseline
时间窗: 52 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
TARGTEPO Treatment for Anemia in PD US TrialAnemia of End Stage Renal DiseaseNCT02468414Aevi Genomic Medicine, LLC, a Cerecor company3
已完成
1 期
TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)Chronic Kidney DiseaseEnd Stage Renal DiseaseNCT02117427Aevi Genomic Medicine, LLC, a Cerecor company11
已完成
1 期
Safety and Efficacy of Sustained Erythropoietin TherapyAnemiaNCT00542568Medgenics Medical Israel Ltd.19
终止
3 期
Evaluation of Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study Versus Methylprednisolone (MP)Spinal Cord InjuryNCT00561067Niguarda Hospital10
招募中
4 期
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA NephropathyNCT06712407Calliditas Therapeutics AB60